Cardinal Health Aktie News

Dividend stocks are a favorite among investors for good reason.

Dividend Aristocrats have underperformed the S&P 500 in 2025, with NOBL up 1.77% versus SPY's 5.55% year-to-date gain. Dividend growth remains healthy, with 44 out of 69 Aristocrats already raising payouts in 2025 and an average growth rate of 4.86%. I identified 21 Aristocrats as both potentially undervalued and offering a projected long-term annualized return of at least 10%.

The magic of dividends is that you don't need to do anything to earn them aside from holding the stocks that pay them. Someone who accumulates enough dividend stocks could live off their portfolio's passive income stream and never have to work another day in their life.

Drug distributor Cardinal Health raised its annual adjusted profit forecast on Thursday, banking on demand for costly specialty medicines and branded drugs at its pharmaceuticals unit.

Key announcements: Raising FY25 non-GAAP diluted EPS guidance to $8.15 to $8.20 1 Establishing preliminary FY26 non-GAAP diluted EPS guidance of $9.10 to $9.30 (13% growth at the mid-points)2 Confirming long-term target of 12% to 14% non-GAAP diluted EPS CAGR for FY26 to FY283 Raising long-term target for Pharmaceutical and Specialty Solutions profit to 5% to 7% normalized growth3,4 Raising lon...

Kendall DL™ Multi System simplifies patient monitoring, drives efficiencies for providers  DUBLIN, Ohio , June 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today the U.S. launch of its multi-parameter, single-patient use monitoring cable and lead wire system that enables the continuous monitoring of cardiac activity, blood oxygen level and temperature with one point of connecti...

Retirement can be daunting, but it doesn't need to be.

Dividend Aristocrats have slightly outperformed the S&P 500 year-to-date, despite underperforming in April and May. Dividend growth remains robust, with 41 of 69 Aristocrats announcing increases in 2025 and the average growth rate at 4.75%. 22 Aristocrats appear both undervalued and offer a projected long-term annualized return of at least 10%, based on dividend yield theory and earnings growth.